An epidermal nevus (plural: nevi) is an abnormal, noncancerous (benign) patch of skin caused by an overgrowth of cells in the outermost layer of skin (epidermis). Epidermal nevi are typically seen at birth or develop in early childhood. Affected individuals have one or more nevi that vary in size.
Several genes have been associated with different types of epidermal nevus. Mutations in the FGFR3 gene and PIK3CA gene account for about forty percent of keratinocytic epidermal nevi. Mutations in the HRAS gene are found in a majority of people with a nevus sebaceous and are also associated with keratinocytic epidermal nevi. Genes related to HRAS (called KRAS and NRAS) are less commonly involved in nevi sebaceous or keratinocytic epidermal nevi. Other genes, some of which have not been identified, are also involved in epidermal nevi.
Epidermal nevi are estimated to occur in 1 to 3 in 1,000 people.
This condition is generally not inherited but arises from mutations in the body's cells that occur after conception. This type of alteration is called a somatic mutation.
Rudolf Happle practices in Freiburg, Germany. Happle is rated as an Elite expert by MediFind in the treatment of Epidermal Nevus. He is also highly rated in 58 other conditions, according to our data. His top areas of expertise are Cutis Marmorata Telangiectatica Congenita, Epidermal Nevus, Focal Dermal Hypoplasia, and Mosaicism.
Christian Hafner practices in Regensburg, Germany. Hafner is rated as an Elite expert by MediFind in the treatment of Epidermal Nevus. He is also highly rated in 7 other conditions, according to our data. His top areas of expertise are Epidermal Nevus, Seborrheic Keratosis, Linear Nevus Sebaceous Syndrome, and Liver Spots.
Roni Gad-Dodiuk practices in Toronto, Canada. Gad-Dodiuk is rated as an Elite expert by MediFind in the treatment of Epidermal Nevus. She is also highly rated in 6 other conditions, according to our data. Her top areas of expertise are Darier Disease, Erythema Multiforme, Stevens-Johnson Syndrome, and Epidermal Nevus.
Summary: This study of NFX-179 is an open-label study, evaluating safety, tolerability, pharmacodynamic activity, and the clinical effect in subjects with Epidermal Nevus(ENS). NFX-179 is formulated as a gel for topical administration. NFX-179 has been shown in animal studies and in human extracts to suppress p-ERK with systemic absorption of NFX-179 following topical application to be extremely low, based...
Summary: This validation study aims to develop a standardised investigator global assessment (IGA) score for keratosis pilaris and test the validity and reliability of the score through a one-day scoring exercise held at a private practice and compare it to a standard 0-4 IGA score specifically defined for keratosis pilaris.
Published Date: August 01, 2016Published By: National Institutes of Health